A flurry of deals suggests that drug firms favour buying their way out of trouble.
Acadia’s Daybue begins commercial launch as the first approved treatment for Rett Syndrome, following a recent FDA approval.
After circling around the crop of biotechs ripe for a takeover, Big Pharma companies have finally decided to strike.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.